The response to secondary therapy, chemotherapy or hormonal, is examined in 26 patients with adenocarcinoma of breast who failed adjuvant chemotherapy. Response rates to tamoxifen or combination chemotherapy, cyclophosphamide, methotrexate, and 5-FU (CMF) or Adriamycin and vincristine (AV) were similar to response rates reported for Stage IV patients, never exposed to cytotoxic agents. Survivals in these 26 patients were similar to those reported for Stage IV patients never exposed to cytotoxics. It is concluded that adjuvant chemotherapy does not lessen future response to secondary therapies or decrease survival.

Download full-text PDF

Source
http://dx.doi.org/10.1002/1097-0142(19830201)51:3<381::aid-cncr2820510304>3.0.co;2-zDOI Listing

Publication Analysis

Top Keywords

response secondary
12
adjuvant chemotherapy
12
secondary therapy
8
patients adenocarcinoma
8
adenocarcinoma breast
8
chemotherapy response
8
response rates
8
reported stage
8
stage patients
8
patients exposed
8

Similar Publications

Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.

View Article and Find Full Text PDF

Background: The rapid mutation of avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Herein, we have successfully developed an mRNA-LNPs candidate vaccine for H5 subtype highly pathogenic avian influenza and evaluated its immunogenicity and protective efficacy.

Results: In experiments on BALB/c mice, the vaccine candidate elicited strong humoral and a certain cellular immune responses and protected mice from the heterologous AIV challenge.

View Article and Find Full Text PDF

Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for secondary treatment.

Int J Hematol

January 2025

Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.

The study aimed to investigate the therapeutic effect of various initial treatments incorporating glucocorticoid (GC) in TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly). Cases of TAFRO syndrome up to November 2023 were retrospectively collected. Overall survival (OS) and resistance to GC therapy were assessed, with resistance analyzed based on the time to the next treatment or death (TTNTD).

View Article and Find Full Text PDF

Tissue microenvironments are extremely complex and heterogeneous. It is challenging to study metabolic interaction between the different cell types in a tissue with the techniques that are currently available. Here we describe a multimodal imaging pipeline that allows cell type identification and nanoscale tracing of stable isotope-labeled compounds.

View Article and Find Full Text PDF

Purpose: Blood lactate concentration is commonly used to assess metabolic demand and skeletal muscle training response. The objective of the pilot study was to investigate if a change in blood lactate was detectable in an anaerobically designed vocal demand task vocal capacity anaerobic task (VCAT) and determine if the developed vocal demand task may assess the anaerobic capacity of the voice musculature, like anaerobic power tests commonly used in applied exercise science.

Methods: A prospective repeated measures study quantified blood lactate concentration preVCAT and postVCAT in vocally healthy adults.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!